经心尖J-Valve瓣膜系统治疗高危重度主动脉瓣疾病的临床结果
该研究纳入107例高危重度主动脉瓣疾病患者,经心尖植入J-Valve瓣膜系统,包含63例主动脉瓣狭窄和44例主动脉瓣反流患者。瓣膜成功植入率95.3%,30天和6个月总体死亡率均为4.7%,狭窄组平均跨瓣压差从56.7 mmHg降至14.4 mmHg(P<.01)。J-Valve经心尖TAVR是治疗高危重度主动脉瓣狭窄或反流的可行临床选择。
要点
- J-Valve瓣膜成功植入率95.3%,5例(4.7%)转为开放手术。
- 30天和6个月总体死亡率均为4.7%,狭窄组6.3%、反流组2.3%。
- 狭窄组术后平均跨瓣压差由56.7降至14.4 mmHg(P<.01)。
核心结论
- 经心尖J-Valve瓣膜系统是治疗高危重度主动脉瓣狭窄或主动脉瓣反流的可行临床选择。
研究设计与样本
- 单中心前瞻性观察研究,2014年3月至2015年7月纳入107例高危患者(平均年龄74.4±5.2岁),其中主动脉瓣狭窄63例、主动脉瓣反流44例。
- 采用超声心动图和增强CT评估基线特征及随访情况。
主要发现
- J-Valve成功植入102例(95.3%),5例(4.7%)转为开放手术。
- 30天和6个月总体死亡率均为4.7%(n=5),狭窄组6.3%(n=4),反流组2.3%(n=1)。
- 永久起搏器植入5例(4.7%)。
- 狭窄组术后瓣周漏无或微量54.2%(n=32)、轻度42.4%(n=25)、中度3.4%(n=2);平均跨瓣压差从56.7±15.2 mmHg降至14.4±7.8 mmHg(P<.01),峰值流速从4.76±0.6 m/s降至2.45±0.57 m/s(P<.01)。
- 反流组术后瓣周漏无或微量74.4%(n=32)、轻度23.3%(n=10)、2.3%(n=1);平均跨瓣压差7.1±2.9 mmHg。
临床怎么用
- 对于高危重度主动脉瓣狭窄或反流患者,经心尖J-Valve瓣膜系统可作为TAVR的备选方案。
- 术后需用超声心动图评估瓣周漏和跨瓣压差,并监测永久起搏器植入需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The clinical experience of a novel transapical transcatheter aortic valve replacement system, the J-Valve (JC Medical Inc, Burlingame, Calif), in high-risk patients with severe aortic valve diseases is limited. METHODS: A total of 107 high-risk patients (mean age, 74.4 ± 5.2 years) underwent transcatheter aortic valve replacement with the J-Valve from March 2014 to July 2015, which included 63 patients with aortic stenoses and 44 patients with aortic regurgitation. Echocardiography and contrast-enhanced computed tomography were used to evaluate patients' baseline characteristics and their follow-up conditions. RESULTS: The J-Valve was successfully implanted in 102 patients (95.3%). Five patients (4.7%) underwent conversion to open surgery. The overall mortality was 4.7% (n = 5) at both 30 days and 6 months, whereas subgroup mortality was 6.3% (n = 4) in the aortic stenosis group and 2.3% (n = 1) in the aortic regurgitation group. Permanent pacemakers were implanted in 5 patients (4.7%). In the aortic stenosis group, paravalvular regurgitation was observed as none or trace in 54.2% of patients (n = 32), mild in 42.4% of patients (n = 25), and moderate in 3.4% of patients (n = 2) postprocedure. The mean aortic gradient decreased from 56.7 ± 15.2 mm Hg to 14.4 ± 7.8 mm Hg (P < .01). The peak aortic valve velocity declined from 4.76 ± 0.6 m/s to 2.45 ± 0.57 m/s (P < .01). In the patients with aortic regurgitation, paravalvular regurgitation was none or trace in 74.4% (n = 32), mild in 23.3% (n = 10), and 2.3% (n = 1) after the procedure. Mean aortic gradient was 7.1 ± 2.9 mm Hg. CONCLUSIONS: Transcatheter aortic valve replacement by the J-Valve is an adequate clinical option to treat high-risk patients with severe aortic stenosis or aortic regurgitation.
引用
- Zhu L, Guo Y, Wang W, et al. Transapical transcatheter aortic valve replacement with a novel transcatheter aortic valve replacement system in high-risk patients with severe aortic valve diseases. J Thorac Cardiovasc Surg. 2017. PMID: 28992963. doi:10.1016/j.jtcvs.2017.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。